

Plasma antioxidant vitamins, chronic hepatitis B virus infection and urinary aflatoxin B₁–DNA adducts in healthy males

Ming-Whei Yu¹, Yi-Ching Chiang¹, Ju-Ping Lien¹ and Chien-Jen Chen^{1,2}

School of Public Health, College of Public Health, National Taiwan University, Taipei 100, Taiwan and ¹Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, No. 1 Jen-Ai Rd. Sec. 1, Taipei 100, Taiwan

²To whom correspondence should be addressed

Epidemiological evidence indicates that aflatoxin B₁ (AFB₁) intake is associated with an increased risk of hepatocellular carcinoma (HCC). The hepatocarcinogenesis is initiated by covalent binding of AFB₁ to cellular DNA. To determine whether nutritional factors and hormonal status may influence the binding of AFB₁ to hepatic DNA, a cross-sectional study was performed on a total of 42 male asymptomatic hepatitis B surface antigen (HBsAg) carriers and 43 male non-carriers in a cohort study on the multistage development of HCC in Taiwan. The major AFB₁–DNA adduct *in vivo*, AFB₁–N⁷-guanine, was measured by high-performance liquid chromatography in urine. Urinary AFB₁–N⁷-guanine was detectable in 40% of the subjects. HBsAg carriers had a higher detection rate of urinary AFB₁–DNA adducts than non-carriers and the difference was statistically significant after multivariate adjustment. After taking into account the total AFB₁ urinary metabolite level, chronic HBsAg carrier status, and other potential confounders, plasma levels of cholesterol, α -tocopherol, and α - and β -carotene were positively associated with the detection rate of the AFB₁–DNA adducts in a dose-dependent manner, whereas plasma lycopene level was inversely related to the presence of the adducts in urine. The association of urinary AFB₁–DNA adducts with the plasma levels of cholesterol, α -tocopherol, lycopene, and α - and β -carotene was observed at both low and high exposure levels of AFB₁. There was a synergistic interaction of plasma α -tocopherol with α - and β -carotene on the adduct levels. No association with the adducts was found for plasma levels of retinol and testosterone. This study demonstrated different associations of antioxidant vitamins with AFB₁–DNA adduct formation. The data consistent with our previous finding in cultured woodchuck hepatocytes that α -tocopherol and β -carotene enhanced AFB₁–DNA adduct formation suggest that prospective investigation of the relationship between plasma micronutrients and risk of AFB₁-related HCC is warranted.

Introduction

Ingestion of aflatoxin B₁ (AFB₁*) and chronic infection with hepatitis B virus (HBV) have been identified as major risk

factors for the development of hepatocellular carcinoma (HCC) in Taiwan and other parts of southeastern Asia and Africa (1–5). AFB₁ is carcinogenic in many animal species and its covalent binding to hepatic DNA has been shown to be a critical step in hepatocarcinogenesis (6).

The major AFB₁–DNA adduct formed *in vivo* is AFB₁–N⁷-guanine (7). Treatment of AFB₁ to rats resulted in the urinary excretion of AFB₁–N⁷-guanine adducts. The adduct excretion following AFB₁ administration was shown to be proportional to the total amount of AFB₁–N⁷-guanine initially formed in the hepatic DNA (8). Although the presence of AFB₁–DNA adducts in liver specimens is readily detected by immunohistochemical methods (3), liver tissues are usually difficult to obtain. Measurement of the adduct levels in urine provides a non-invasive means of estimating the degree of AFB₁ binding to hepatic DNA. It has been used as an intermediate endpoint in cancer prevention trials for assessing the efficacy of chemopreventive agents that may have an inhibitory effect at early stages of AFB₁-induced hepatocarcinogenesis (6,9). The relationship between urinary AFB₁–N⁷-guanine adducts and HCC risk was recently investigated in a prospective study and the presence of the DNA adduct in urine has been shown to be a significant predictor for the cancer risk (4).

In addition to chronic HBV infection and aflatoxin exposure, our previous epidemiological studies have linked many risk factors, including hepatitis C virus (HCV), alcohol drinking, cigarette smoking, elevated serum level of endogenous testosterone, low serum retinol level and/or vegetable consumption, as well as genetic susceptibility, to the development of HCC (10–15). There may be a complex interaction among multiple HCC risk factors at various stages of hepatocarcinogenesis. We previously examined the effect of chronic HBV infection, sociodemographic characteristics, and habits of cigarette smoking and alcohol drinking on AFB₁–DNA adduct formation (16). Age and habits of cigarette smoking and alcohol drinking were found to be positively associated with the adduct levels. Whether other factors may influence the binding of AFB₁ to hepatic DNA have yet to be identified. Synthetic antioxidants have been reported to inhibit AFB₁–DNA adduct formation and thus the tumorigenicity of AFB₁ in rats (17,18). Experimental studies have also suggested that dietary antioxidants such as vitamin C, vitamin E and several carotenoids may suppress chemically induced carcinogenesis through a variety of mechanisms, including reduction of oxidative DNA damage, modulation of carcinogen-metabolizing enzymes, and/or trapping of electrophilic forms of carcinogens (19–21). However, vitamin E and β -carotene were observed to enhance AFB₁–DNA adduct formation in our previous *in vitro* study on cultured woodchuck hepatocytes (22). In addition to the environmental agents, hormonal status may also influence the AFB₁ binding to DNA. The pathway leading to metabolic activation of AFB₁ was reported to be more active in male than in female rats (23). The role of endogenous testosterone in AFB₁ metabolism in humans

*Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFB₁, aflatoxin B₁; AFB₁–N⁷-guanine, 8,9-dihydro-8-(N⁷-guanyl)-9-hydroxy-aflatoxin B₁; HBsAg, hepatitis B surface antigen; HPLC, high-performance liquid chromatography; OR, odds ratio; CI, confidence interval.

remains to be explored. This study was carried out to elucidate the potential roles of endogenous testosterone and nutritional factors including common antioxidants at the early stage of AFB₁-induced hepatocarcinogenesis by investigating the covalent binding of AFB₁ to hepatic DNA. Urinary AFB₁-N⁷-guanine was used as a biomarker for assessing AFB₁-DNA binding in the liver.

Materials and methods

Study subjects

The subjects of the present study have been described in a previous publication that examined associations of multiple factors with urinary levels of AFB₁-DNA adducts (16). Initially, a total of 43 male asymptomatic HBsAg carriers and 43 male HBsAg non-carriers were included in the study. HBsAg non-carriers were matched with the carriers on age (± 5 years) and time of biospecimen collection (± 3 months). They were randomly selected from the cohort members without HCC in a prospective study on the multifactorial etiology of multistage hepatocarcinogenesis in Taiwan. The cohort characteristics and method of follow-up have been described in a previous study (15). The urine and blood samples from study subjects were consecutively collected between August 1988 and June 1992. Urine samples were kept frozen at -30°C and blood samples were kept at -70°C until they were used in the present analyses. At the time of urine and blood collection, each study subject was also personally interviewed to obtain information related to habits of cigarette smoking and alcohol drinking, dietary pattern and health history. In the present analysis, study subjects were 42 HBsAg carriers and 43 HBsAg non-carriers whose plasma samples were sufficient for analysis of micronutrients and testosterone. All the chronic HBsAg carriers included in this study remained asymptomatic throughout a 5-year follow-up period, except two who were subsequently affected with liver cirrhosis. The mean duration of biospecimen storage prior to testing is 4.4 years (range: 2.4–6.3 years). There was no significant difference in seasons of biospecimen collection between HBsAg carriers and non-carriers.

Laboratory analyses

Serum HBsAg was assayed using a radioimmunoassay (Abbott Laboratories, North Chicago, IL). All but six study subjects were also tested for antibodies against HCV (anti-HCV). Anti-HCV was examined by a second-generation enzyme immunoassay (Abbott Laboratories, North Chicago, IL). The urine samples were assayed for levels of AFB₁, two of its main metabolites (AFM₁ and AFP₁) and the AFB₁-N⁷-guanine adducts. Urinary AFB₁ metabolites were quantified by high-performance liquid chromatography (HPLC) as described previously (16). In short, aflatoxin metabolites were extracted from a 5-ml aliquot of urine. Analysis of various aflatoxin metabolites was done on an HPLC gradient liquid chromatograph with a Waters model 470 fluorescence detector (Waters Associates, Milford, MA). The HPLC column was a C₁₈ 10- μm (3.9 mm inside diameter \times 30 cm length) μ Bondpak column (Waters). For analysis of AFM₁, AFB₁-N⁷-guanine, and AFP₁, chromatographic separation was achieved by elution for 12 min with 15% acetonitrile followed by 22% acetonitrile in water. The flow rates were 1.5, 0.8, 0.3 and 1.0 ml/min at 0–12, 13–21, 22–35 and 36–41 min, respectively. Elutes were measured by fluorescence detection with 365 nm excitation and 430 nm emission wavelength for AFM₁, and 500 nm emission for AFB₁ and AFB₁-N⁷-guanine. The HPLC analysis for AFP₁ was done with a 30-min elution with 12% acetonitrile followed by a 12–22% acetonitrile linear gradient generated over 12 min, then elution at 22% acetonitrile. The flow rates were 1.5, 0.3, 1.5, 0.3, 1.0 and 0.3 ml/min at 0–17, 18–19, 20–29, 30–41, 42–44 and 45–52 min, respectively. AFP₁ was measured by monitoring the fluorescence emission at 500 nm with the excitation wavelength at 365 nm. Authentic aflatoxin standards were used to determine chromatographic retention times. All aqueous mobile phases before use were adjusted by orthophosphoric acid and triethylammonium formate buffer to pH 3.0. Plasma micronutrients were also measured by HPLC using a modification of the method by Miller and Yang (24). Plasma testosterone levels were determined by a radioimmunoassay kit (Biomerieux, Marcy l'Etoile, France).

Statistical methods

Odds ratios (ORs) and their 95% confidence intervals (CIs) were computed to examine the associations of the positivity of urinary AFB₁-N⁷-guanine with various variables. Mantel's chi-square test for a trend was performed to examine the dose-response relationship for the odds ratios. Logistic regression was used to estimate ORs when adjusting covariates.

Results

The age range of the subjects was 33 to 66 years, with a mean age of 51.5 years (± 9.8 SD). Only two HBsAg carriers and

two HBsAg non-carriers were positive for anti-HCV. AFM₁ was observed as the most abundant AFB₁ metabolite excreted. The mean level of total AFB₁ urinary metabolites (including AFB₁, AFM₁, AFP₁, and AFB₁-N⁷-guanine) was 9.47 ng/ml (± 16.89 SD). Forty percent (34/85) of the urine samples contained a detectable level of AFB₁-N⁷-guanine adducts. The mean level of AFB₁-N⁷-guanine adduct in the positive urine samples was 0.52 ng/ml (± 1.02 SD). More than 90% of the study subjects had a urinary AFB₁-N⁷-guanine adduct level $< 10\%$ of the total AFB₁ metabolites excreted in the urine.

In univariate analysis, the odds ratios associated with the positivity of urinary AFB₁-N⁷-guanine were elevated with increasing plasma levels of α -tocopherol (P for trend = 0.005) and β -carotene (P for trend = 0.018). No significant association with the AFB₁-DNA adducts in urine was observed for chronic HBsAg carrier status and plasma levels of testosterone and other nutrients. Since there were correlations among various plasma nutrients, logistic regression analysis was adopted to estimate multivariate-adjusted ORs associated with the positivity of urinary AFB₁-DNA adducts. After taking into account other potential confounders including the total AFB₁ urinary metabolites, plasma α -tocopherol level retained its significance. Chronic HBsAg carrier status and plasma cholesterol level were also significant factors associated with the positivity of urinary AFB₁-DNA adducts. Increase in the detection rate of the adducts was related to the plasma α -carotene at a borderline significant level (high versus low tertile, $P = 0.0548$). Although a positive association was also observed between plasma β -carotene levels and urinary AFB₁-DNA adducts, this association was not statistically significant. Plasma lycopene level was inversely associated with the positivity of the adducts. No significant association with urinary AFB₁-DNA adducts was found for plasma retinol and testosterone. Because plasma levels of α -carotene and β -carotene were highly correlated ($r = 0.64$) and the two carotenoids associated with urinary AFB₁-DNA adducts in a similar manner, the levels of the two carotenoids were therefore combined in the analysis. This made almost no change in the ORs of the positivity of urinary AFB₁-DNA adducts with other variables. There was a significant positive association between the adducts and plasma levels of α - and β -carotene (Table I).

Table II shows the detection rate of AFB₁-N⁷-guanine in urine by levels of total AFB₁ urinary metabolites and plasma nutrients. Due to the sample size not being large, study subjects were categorized into only two groups according to the median of their distribution. The association of urinary AFB₁-DNA adducts with the plasma levels of cholesterol, α -tocopherol, and α - and β -carotene was observed at both low and high exposure levels of AFB₁. The multivariate-adjusted ORs associated with the positivity of the AFB₁-DNA adducts in urine suggested a strong synergistic interaction of AFB₁ exposure with plasma levels of these nutrients. In contrast, lycopene appeared to have an inhibitory effect on AFB₁-DNA adduct formation at low and high AFB₁ exposure. Interactive effect between plasma α -tocopherol and α - and β -carotene on the adduct levels is depicted in Table III. All the ORs associated with the positivity of urinary AFB₁-DNA adducts in relation to various variables in this study were not materially changed when adjustment was also made for storage time of biospecimens and seasons of collecting biospecimens.

Table I. Associations of the positivity of urinary AFB₁-N⁷-guanine adducts with HBsAg carrier status and plasma levels of testosterone and various nutrients

Variable	AFB ₁ -N ⁷ -guanine		Crude OR	Multivariate-adjusted OR (95% CI) ^a	P
	Negative	Positive			
HBsAg carrier status					
Negative	28	15	1.0	1.0	
Positive	23	19	1.54	7.52 (1.51–37.53)	0.0138
Testosterone (ng/ml)					
≤4.7 ^b	17	11	1.0	1.0	
4.8–5.9	16	12	1.16	1.89 (0.33–10.77)	0.4739
>5.9	18	11	0.94	0.93 (0.16–5.50)	0.9342
Cholesterol (mg/dl)					
≤178.7 ^b	19	10	1.0	1.0	
178.8–216.7	20	9	0.86	0.75 (0.15–3.71)	0.7287
>216.7	12	15	2.38	6.99 (1.24–39.44)	0.0276
Retinol (μg/dl)					
≤43.0 ^b	18	10	1.0	1.0	
43.1–58.0	19	9	0.85	0.57 (0.10–3.13)	0.5169
>58.0	14	15	1.93	1.86 (0.32–10.91)	0.4911
α-Tocopherol (μg/dl)					
≤621.0 ^b	22	7	1.0 ^c	1.0	
621.1–829.0	17	9	1.66	1.88 (0.28–12.71)	0.5162
>829.0	12	18	4.71	11.20 (1.47–85.59)	0.0199
Lycopene (μg/dl)					
≤14.3 ^b	20	8	1.0	1.0	
14.4–21.7	15	13	2.17	0.22 (0.02–2.68)	0.2343
>21.7	16	13	2.03	0.04 (0.002–0.79)	0.0342
α-Carotene + β-carotene (μg/dl)					
≤13.4 ^b	21	7	1.0 ^c	1.0	
13.5–22.7	17	10	1.76	7.77 (0.65–93.56)	0.1064
>22.7	13	17	3.92	33.12 (1.58–695.66)	0.0243

^aAll the variables shown in the table, total AFB₁ urinary metabolites, age and habits of cigarette smoking and alcohol drinking were also included in the multiple logistic regression model.

^bCategorized according to the tertile distribution of subjects.

^cTest for trend was statistically significant.

Table II. Detection rate of urinary AFB₁-N⁷-guanine adducts by total AFB₁ metabolites in urine and plasma levels of selected nutrients

Variable	Total no.	Detection rate of AFB ₁ -N ⁷ -guanine (%)	Crude OR	Multivariate-adjusted OR (95% CI) ^a	P
Total urinary AFB ₁ /α-tocopherol					
Low/low ^b	22	4.5	1.0 ^c	1.0	
Low/high	20	45.0	17.18	22.56 (1.64–309.74)	0.0197
High/low	21	47.6	19.09	41.83 (2.99–584.57)	0.0055
High/high	22	63.6	36.75	73.19 (4.56–1173.76)	0.0024
Total urinary AFB ₁ /α-carotene + β-carotene					
Low/low	24	12.5	1.0 ^c	1.0	
Low/high	18	38.9	4.45	8.63 (1.03–72.34)	0.0470
High/low	19	47.4	6.30	8.10 (1.25–52.29)	0.0280
High/high	24	62.5	11.67	27.68 (3.33–230.41)	0.0021
Total urinary AFB ₁ /lycopene					
Low/high	21	28.6	1.0 ^c	1.0	
Low/low	21	19.0	0.59	3.02 (0.27–34.35)	0.3725
High/high	21	57.1	3.33	3.45 (0.62–19.02)	0.1556
High/low	22	54.5	3.00	32.55 (3.22–329.40)	0.0032
Total urinary AFB ₁ /cholesterol					
Low/low	23	21.7	1.0 ^c	1.0	
Low/high	19	26.3	1.29	1.54 (0.21–11.31)	0.6701
High/low	21	47.6	3.27	4.04 (0.69–23.52)	0.1204
High/high	22	63.6	6.30	11.03 (1.78–68.16)	0.0098

^aAge, HBsAg carrier status, habits of cigarette smoking and alcohol drinking and plasma levels of testosterone and other nutrients were also included in the multiple logistic regression model.

^bHigh and low level was categorized according to the median of study subjects.

^cTest for trend was statistically significant.

Table III. Detection rate of urinary AFB₁-N⁷-guanine adducts by plasma levels of α -tocopherol and α -carotene plus β -carotene

α -Tocopherol/ α -carotene + β -carotene	Total no.	Detection rate of AFB ₁ -N ⁷ -guanine (%)	Crude OR	Multivariate-adjusted OR (95% CI) ^a	P
Low/low ^b	25	20.0	1.0 ^c	1.0	
Low/high	18	33.3	2.00	8.19 (0.74–90.77)	0.0867
High/low	18	38.9	2.55	7.30 (0.96–55.30)	0.0543
High/high	24	66.7	8.00	29.43 (2.94–294.27)	0.0040

^aAge, total AFB₁ urinary metabolites, habits of cigarette smoking and alcohol drinking, HBsAg carrier status and plasma levels of testosterone and other nutrients were also included in the multiple logistic regression model.

^bHigh and low level was categorized according to the median of study subjects.

^cTest for trend was statistically significant.

Discussion

The data on urinary aflatoxins were based on spot urine samples. Although no adjustment was made for urine concentration in the calculation of AFB₁-N⁷-guanine excretion in this study, this may not pose significant problems for investigation of the associations between various variables and the positivity of urinary AFB₁-DNA adducts, because total quantity of AFB₁ metabolites excreted in urine was included in the multivariate analyses as a covariate for adjusting its effect.

Epidemiological studies suggest that HBV and AFB₁ may exert a synergistic effect on the development of HCC (4). The mechanisms responsible for this interaction remain to be elucidated. In woodchucks, chronic infection with woodchuck hepatitis virus, a virus similar in characteristics to HBV, produced an enhanced metabolic activation of chemical carcinogen, including AFB₁ (25). However, epidemiological studies of the relationship between HBsAg carrier status and the formation of AFB₁-DNA adducts, using AFB₁-albumin adduct or urinary AFB₁-N⁷-guanine as the surrogate dosimeter for estimating hepatic DNA binding by AFB₁, have been inconsistent (16,26–28). We have previously demonstrated that the detection rate of urinary AFB₁-N⁷-guanine adducts was higher in HBsAg carriers than in non-carriers, but this association was not statistically significant in univariate analysis or in a multivariate analysis including the total AFB₁ urinary metabolites, age, and habits of cigarette smoking and alcohol drinking, as covariates (16). In the present study, HBsAg carrier status was strongly associated with urinary AFB₁-DNA adduct levels after adjustment was made for plasma nutrients and other potential confounders. The discrepancy between our two studies may be due to the difference in the control of plasma nutrients that were significantly associated with the AFB₁-DNA adduct levels. The possible biological mechanisms for HBV involvement in the genesis of HCC have been extensively reviewed (1). This study provides evidence that chronic HBV infection may interact with AFB₁ intake in the initiation process of hepatocarcinogenesis and thus result in an increased risk of AFB₁-related HCC.

HCC is two to three times more frequent in men than in women (1). The marked sex difference in susceptibility to hepatocarcinogenesis was also observed in various animal models (29–31). A relationship between elevated serum testosterone level and HCC risk in humans has been documented (12). In experimental studies, the mechanism for the action of testosterone in hepatocarcinogenesis may be through its effects on promotion of the growth of tumor and/or modulation of the activity of enzymes involved in metabolism of hepatocarcinogens (23,30). For a given level of AFB₁ exposure, male rats were found to produce more AFB₁-epoxide, which can form

adducts with DNA, than female rats (23). However, variation in plasma testosterone levels was not correlated with AFB₁-DNA adducts in this study.

Low serum retinol level has been associated with the development of various human cancers, including HCC (14). Liver fractions from rats with vitamin A-deficiency formed a higher level of DNA adducts by AFB₁ (32). Our previous *in vitro* study with cultured woodchuck hepatocytes demonstrated a potent inhibitory effect of retinol on AFB₁-DNA adduct formation (22). However, we failed to find a significant association of AFB₁-DNA adducts with plasma retinol levels in this cross-sectional study. The reason for the discrepancy between our *in vitro* and human study is unclear but may be explained by the difference in the effect of retinol between species. On the other hand, since this study was conducted in a well-nourished population with low prevalence of vitamin A-deficiency, whether a more striking association between urinary AFB₁-DNA adducts and plasma retinol level may be shown up in malnourished populations requires further investigations.

Lycopene, α -carotene and β -carotene are carotenoids with a similar chemical structure. They are antioxidant contents of vegetables and fruits (21). Experimental and epidemiological studies on the potential role of α -carotene and lycopene in carcinogenesis are limited (33–37). The influence of β -carotenoids on susceptibility to various forms of cancers have been evaluated in a number of epidemiological studies (38–40). Although the majority of results have shown that high intake and/or high serum level of β -carotene were associated with a reduced risk of cancer at several sites (38,39), some data are conflicting and the significance of β -carotene in carcinogenesis remains unclear (40). The most marked finding of this study was the strong and extremely diverse associations of various carotenoids with AFB₁-N⁷-guanine adducts in urine. α -Carotene and β -carotene were positively associated with the DNA adducts, while the adducts appeared to reduce with increasing plasma levels of lycopene. Difference in the ability of diverse carotenoids to suppress the development of spontaneous HCC and chemically-induced neoplastic transformation, enhance gap junctional communication and regulate gene expression have been shown in experimental studies (34–37). Although the underlying mechanism for the molecular specificity of each of the carotenoids to influence AFB₁-DNA adduct formation is unclear, this study provides additional insight into the complexity of the biological function of carotenoids.

α -Tocopherol is among the most potent antioxidants from natural source (21,36). Several experimental and epidemiological suggest that α -tocopherol may reduce the risk of cancer

(41). The potential use of α -tocopherol in cancer chemoprevention has been evaluated in lung cancer, oral leukoplakia and colorectal polyps. However, epidemiologic evidence for its chemopreventive action is inconsistent (40,42,43). In this study, the detection rate of the AFB₁-DNA adducts in urine was significantly elevated with increasing plasma levels of α -tocopherol. There was a synergistic interaction between α -tocopherol and α - and β -carotene on the DNA adduct levels.

The data demonstrating a positive association between urinary AFB₁-DNA adducts and the plasma levels of α -tocopherol and β -carotene are in accordance with our previous *in vitro* study in which α -tocopherol and β -carotene enhanced the adduct formation in cultured woodchuck hepatocytes (22). Urinary AFB₁-DNA adduct levels can be influenced by carcinogen metabolism and DNA repair. However, it was shown that a supplement with antioxidant vitamins had no significant effect on DNA repair activity (44,45). Thus, our findings cast doubts on the potential role of certain dietary antioxidants, such as α -tocopherol, α -carotene and β -carotene, in prevention of AFB₁-induced DNA damage. However, it is premature to conclude that these antioxidant vitamins have an adverse effect on the development of HCC. The pathogenesis of cancer is a multistage process including DNA alteration and cell proliferation. Vitamins may have multiple biological mechanisms to inhibit or retard one or more stages of carcinogenesis. The association of HCC risk with plasma levels of various antioxidant vitamins remains to be elucidated. On the other hand, our prospective study has demonstrated that an increased risk of HCC is associated with low vegetable intake (14). Vegetables contain a wide variety of phytochemicals with the potential to modulate carcinogenesis (21). Whether constituents in vegetables other than α -carotene and β -carotene may be important protective factors for AFB₁-induced HCC required further studies.

To date we have not found any reports on the effect of cholesterol on AFB₁-DNA adduct formation. The finding of the positive association of plasma cholesterol with urinary AFB₁-DNA adducts in this study warrants further investigation.

Acknowledgements

This study was supported by grants from the National Science Council (NSC 84-2331-B-002-183, NSC 85-2331-B-002-264) and National Institute of Health, Department of Health, Executive Yuan (DOH86-HR-627) of the Republic of China.

References

1. Yu, M.W. and Chen, C.J. (1994) Hepatitis B and C viruses in the development of hepatocellular carcinoma. *Crit. Rev. Oncol. Hematol.*, **17**, 71–91.
2. Chen, C.J., Yu, M.W., Liaw, Y.F., Wang, L.W., Chiamprasert, S., Matin, F., Hirvonen, A., Bell, D.A. and Santella, R.M. (1996) Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. *Am. J. Hum. Genet.*, **59**, 128–134.
3. Chen, C.J., Zhang, Y.J., Lu, S.N. and Santella, R.M. (1992) Aflatoxin B₁ DNA adducts in smeared tumor tissue from patients with hepatocellular carcinoma. *Hepatology*, **16**, 1150–1155.
4. Qian, G.S., Ross, R.K., Yu, M.C., Yuan, J.M., Gao, Y.T., Henderson, B.E., Wogan, G.N. and Groopman, J.D. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. *Cancer Epidemiol. Biomark. Prev.*, **3**, 3–10.
5. Van Rensburg, S.J., Cook-Mozaffari, P., Van Schalkwyk, D.J., Van Der Watt, J.J., Vincent, T.J. and Purchase, I.F. (1985) Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. *Br. J. Cancer*, **51**, 713–726.
6. Kensler, T.W., Egner, P.A., Davidson, N.E., Roebuck, B.D., Pikul, A. and Groopman, J.D. (1986) Modulation of aflatoxin metabolism, aflatoxin-N⁷-guanine formation and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. *Cancer Res.*, **46**, 3924–3931.
7. Croy, R.G., Essigmann, J.M., Reinhold, V.N. and Wogan, G.N. (1978) Identification of the principal aflatoxin B₁-DNA adduct formed *in vivo* in rat liver. *Proc. Natl Acad. Sci. USA*, **75**, 1745–1749.
8. Bennett, R.A., Essigmann, J.M. and Wogan, G.N. (1981) Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B₁-treated rats. *Cancer Res.*, **41**, 650–654.
9. Groopman, J.D., Wogan, G.N., Roebuck, B.D. and Kensler, T.W. (1994) Molecular biomarkers for aflatoxins and their application to human cancer prevention. *Cancer Res.*, **54**, 1907s–1911s.
10. Yu, M.W., You, S.L., Chang, A.S., Lu, S.N., Liaw, Y.F. and Chen, C.J. (1991) Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. *Cancer Res.*, **51**, 5621–5625.
11. Chen, C.J., Yu, M.W., Wang, C.J., Huang, H.Y. and Lin, W.C. (1993) Multiple risk factors of hepatocellular carcinoma: a cohort study of 13737 male adults in Taiwan. *J. Gastroenterol. Hepatol.*, **8**, 83s–87s.
12. Yu, M.W. and Chen, C.J. (1993) Elevated serum testosterone levels and risk of hepatocellular carcinoma. *Cancer Res.*, **53**, 790–794.
13. Yu, M.W., Chen, C.J., Luo, J.C., Brandt-Rauf, P.W., Carney, W.P. and Santella, R.M. (1994) Correlations of chronic hepatitis B virus infection and cigarette smoking with elevated expression of *neu* oncoprotein in the development of hepatocellular carcinoma. *Cancer Res.*, **54**, 5106–5110.
14. Yu, M.W., Hsieh, H.H., Pan, W.H., Yang, C.S. and Chen, C.J. (1995) Vegetable consumption, serum retinol level and risk of hepatocellular carcinoma. *Cancer Res.*, **55**, 1301–1305.
15. Yu, M.W., Gladek-Yarborough, A., Chiamprasert, S., Santella, R.M., Liaw, Y.F. and Chen, C.J. (1995) Cytochrome P-450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. *Gastroenterology*, **109**, 1266–1273.
16. Yu, M.W., Lien, J.P., Liaw, Y.F. and Chen, C.J. (1996) Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B₁-DNA adducts. *Cancer Epidemiol. Biomark. Prev.*, **5**, 613–619.
17. Jhee, E.C., Ho, L.L. and Lotlikar, P.D. (1988) Effect of butylated hydroxyanisole pretreatment on *in vitro* hepatic aflatoxin B₁-DNA binding and aflatoxin B₁-glutathione conjugation in rats. *Cancer Res.*, **48**, 2688–2692.
18. Mandel, H.G., Manson, M.M., Judah, D.J. and Simpson, J.L. (1987) Metabolic basis for the protective effect of antioxidant ethoxyquin on aflatoxin B₁ hepatocarcinogenesis in the rat. *Cancer Res.*, **47**, 5218–5223.
19. Duthie, S.J., Ma, A., Ross, M.A. and Collins, A.R. (1996) Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. *Cancer Res.*, **56**, 1291–1295.
20. Van Lieshout, E.M.M., Peters, W.H.M. and Jansen, J.B.M.J. (1996) Effect of oltipraz, α -tocopherol, β -carotene and phenethylisothiocyanate on rat oesophageal, gastric, colonic and hepatic glutathione, glutathione S-transferase and peroxidase. *Carcinogenesis*, **17**, 1439–1445.
21. Frei, B. (1994) *Natural Antioxidants in Human Health and Disease*. Academic Press, San Diego, California.
22. Yu, M.W., Zhang, Y.J., Blaner, W.S. and Santella, R.M. (1994) Influence of vitamins A, C and E and β -carotene on aflatoxin B₁ binding to DNA in woodchuck hepatocytes. *Cancer*, **73**, 596–604.
23. O'Brien, K., Mose, E., Judah, D. and Neal, G. (1983) Metabolic basis of the species difference to aflatoxin B₁-induced hepatotoxicity. *Biochem. Biophys. Res. Commun.*, **114**, 813–827.
24. Miller, K.W. and Yang, C.S. (1985) An isocratic high-performance liquid chromatography method for the simultaneous analysis of plasma retinol, α -tocopherol and various carotenoids. *Anal Biochem.*, **145**, 21–26.
25. De Flora, S., Hietanen, E., Bartsch, H., Camoirano, A., Izzotti, A., Bagnasco, M. and Millman, I. (1989) Enhanced metabolic activation of chemical hepatocarcinogens in woodchucks infected with hepatitis B virus. *Carcinogenesis*, **10**, 1099–1106.
26. Allen, S.J., Wild, C.P., Wheeler, J.G., Riley, E.M., Montesano, R., Bennett, S., Whittle, H.C., Hall, A.J. and Greenwood, B.M. (1992) Aflatoxin exposure, malaria and hepatitis B infection in rural Gambian children. *Trans. R. Soc. Trop. Med. Hyg.*, **86**, 426–430.
27. Wild, C.P., Fortuin, M., Donato, F., Whittle, H.C., Hall, A.J., Wolf, C.R. and Montesano, R. (1993) Aflatoxin, liver enzymes and hepatitis B virus infection in Gambian children. *Cancer Epidemiol. Biomark. Prev.*, **2**, 555–561.
28. Groopman, J.D., Hall, A.J., Whittle, H., Hudson, G.J., Wogan, G.N., Montesano, R. and Wild, C.P. (1992) Molecular dosimetry of aflatoxin-N⁷-guanine in human urine obtained in the Gambia, west Africa. *Cancer Epidemiol. Biomark. Prev.*, **1**, 221–227.

29. Sawaki,M., Enomoto,K., Takahashi,H., Nakajima,Y. and Mori,M. (1990) Phenotype of preneoplastic and neoplastic liver lesions during spontaneous liver carcinogenesis of LEC rats. *Carcinogenesis*, **11**, 1857–1861.
30. Moore,M.R., Drinkwater,N.R., Miller,E.C., Miller,J.A. and Pitot,H.C. (1981) Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. *Cancer Res.*, **41**, 1585–1593.
31. Kim,C.M., Koike,K., Saito,I., Miyamura,T. and Jay,G. (1991) *HBx* gene of hepatitis B virus induces liver cancer in transgenic mice. *Nature*, **351**, 317–320.
32. Bhattacharya,R.K., Prabhu,A.L. and Aboobaker,V.S. (1989) *In vivo* effect of dietary factors on the molecular action of aflatoxin B₁: role of vitamin A on the catalytic activity of liver fractions. *Cancer Lett.*, **44**, 83–88.
33. Ziegler,R.G., Colavito,E.A., Hartge,P., McAdams,M.J., Schoenberg,J.B., Mason,T.J., Fraumeni,J.F. Jr (1996) Importance of α -carotene, β -carotene and other phytochemicals in the etiology of lung cancer. *J. Natl Cancer Inst.*, **88**, 612–615.
34. Murakoshi,M., Nishino,H., Satomi,Y. *et al.* (1992) Potent preventive action of α -carotene against carcinogenesis: spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by α -carotene than by β -carotene. *Cancer Res.*, **52**, 6583–6587.
35. Bertram,J.S., Pung,A., Churley,M., Kappock IV,T.J., Wilkins,L.R. and Cooney,R.V. (1991) Diverse carotenoids protect against chemically induced neoplastic transformation. *Carcinogenesis*, **12**, 671–678.
36. Zhang,L.X., Cooney,R.V. and Bertram,J.S. (1991) Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: relationship to their cancer chemopreventive action. *Carcinogenesis*, **12**, 2109–2114.
37. Zhang,L.X., Cooney,R.V. and Bertram,J.S. (1992) Carotenoids up-regulate *Connexin43* gene expression independent of their provitamin A or antioxidant properties. *Cancer Res.*, **52**, 5707–5712.
38. Byers,T. and Perry,G. (1992) Dietary carotenes, vitamin C and vitamin E as protective antioxidants in human cancers. *Annu. Rev. Nutr.*, **12**, 139–159.
39. Comstock,G.W., Bush,T.L. and Helzlsouer,K. (1992) Serum retinol, beta-carotene, vitamin E and selenium as related to subsequent cancer of specific sites. *Am. J. Epidemiol.*, **135**, 115–121.
40. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N. Engl. J. Med.*, **330**, 1029–1035.
41. Bertram,J.S., Kolonel,L.N. and Meyskens,F.L. Jr (1987) Rationale and strategies for chemoprevention of cancer in humans. *Cancer Res.*, **47**, 3012–3031.
42. DeCosse,J.J., Miller,H.H. and Lesser,M.L. (1989) Effects of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. *J. Natl Cancer Inst.*, **81**, 1290–1297.
43. Benner,S.E., Wargovich,M.J., Lippman,S.M., Fisher,R., Velasco,M., Winn,R.J. and Hong,W.K. (1994) Reduction in oral mucosa micronuclei frequency following α -tocopherol treatment of oral leukoplakia. *Cancer Epidemiol. Biomark. Prev.*, **3**, 73–76.
44. Wei,Q., Matanoski,G.M., Farmer,E.R., Hedayati,M.A. and Grossman,L. (1994) DNA repair related to multiple skin cancers and drug use. *Cancer Res.*, **54**, 437–440.
45. Hu,J.J., Roush,G.C., Berwick,M., Dubin,N., Mahabir,S., Chandiramani,M. and Boorstein,R. (1996) Effects of dietary supplementation of α -tocopherol on plasma glutathione and DNA repair activities. *Cancer Epidemiol. Biomark. Prev.*, **5**, 263–270.

Received on November 4, 1996; revised on February 7, 1997; accepted on February 20, 1997